Related references
Note: Only part of the references are listed.Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions
Kevin K. Wu et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Kris M. Mahadeo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
Kevin A. Hay et al.
BLOOD (2019)
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Kevin J. Curran et al.
BLOOD (2019)
A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia
Ryan K. DasGupta et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2018)
CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study
Guoqing Wei et al.
ANNALS OF HEMATOLOGY (2018)
A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
Jianyu Weng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
CD19 CAR-T cell therapy for relapsed / refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
Li-Na Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
Ciprian Tomuleasa et al.
FRONTIERS IN IMMUNOLOGY (2018)
Novel Therapies in Acute Lymphoblastic Leukemia
Kathleen W. Phelan et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia
Colleen E. Annesley et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors
I. Aldoss et al.
LEUKEMIA (2017)
Genetic Basis of Acute Lymphoblastic Leukemia
Ilaria Iacobucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical trials of CAR-T cells in China
Bingshan Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial.
Lei Xiao et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia
Vasthie Prudent et al.
PALLIATIVE & SUPPORTIVE CARE (2017)
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Guoqing Wei et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2015)
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Ching-Hon Pui et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)
Sarah K. Tasian et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2015)
Chimeric Antigen Receptor Therapy for Cancer
David M. Barrett et al.
ANNUAL REVIEW OF MEDICINE, VOL 65 (2014)
Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia
Shira Dinner et al.
LEUKEMIA & LYMPHOMA (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Acute lymphoblastic leukaemia
Hiroto Inaba et al.
LANCET (2013)
Genetically Modified T Cells for the Treatment of Malignant Disease
Agnieszka Wieczorek et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2013)
Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases
J-Q Mi et al.
LEUKEMIA (2012)
Newly diagnosed acute lymphoblastic leukemia in China (I): abnormal genetic patterns in 1346 childhood and adult cases and their comparison with the reports from Western countries
B. Chen et al.
LEUKEMIA (2012)
Molecular origins of cancer - Cancer immunology
Olivera J. Finn
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
Adele K. Fielding et al.
BLOOD (2007)
Share Paper
